

- [54] **SLOW-RELEASE SODIUM FLUORIDE TABLET AND METHOD FOR TREATMENT OF OSTEOPOROSIS**
- [75] Inventors: Neill B. Walsdorf; Charles Y. C. Pak, Dallas, both of Tex.
- [73] Assignees: Mission Pharmacal Company, San Antonio; Board of Regents, The University of Texas System, Austin, both of Tex.
- [21] Appl. No.: 112,202
- [22] Filed: Oct. 22, 1987

**Related U.S. Application Data**

- [63] Continuation-in-part of Ser. No. 842,304, Mar. 21, 1986, Pat. No. 4,726,952, which is a continuation-in-part of Ser. No. 522,014, Aug. 11, 1983, abandoned.
- [51] Int. Cl.<sup>4</sup> ..... A61K 9/22; A61K 9/26
- [52] U.S. Cl. .... 424/468; 424/469; 424/470; 424/484; 424/502
- [58] Field of Search ..... 424/468, 469, 470, 484, 424/502

**References Cited**

**U.S. PATENT DOCUMENTS**

|           |         |                      |         |
|-----------|---------|----------------------|---------|
| 3,062,720 | 11/1962 | Costello .....       | 167/82  |
| 3,402,240 | 9/1968  | Cain et al. ....     | 424/22  |
| 3,577,514 | 5/1971  | Robinson .....       | 424/22  |
| 3,653,914 | 4/1972  | Schmitt .....        | 99/78   |
| 4,104,370 | 8/1978  | Bloch .....          | 424/153 |
| 4,185,093 | 1/1980  | Carnes et al. ....   | 424/153 |
| 4,405,596 | 9/1983  | Helbig et al. ....   | 424/33  |
| 4,614,648 | 9/1986  | Bru .....            | 424/44  |
| 4,726,952 | 2/1988  | Walsdorf et al. .... | 424/476 |

**OTHER PUBLICATIONS**

- Reg. T.M. 1,300,132, Reg. 10/16/1984, Slow Fluoride, (Mission Pharmacal), (First Use in Commerce, Nov. 19, 1982).
- Walsdorf, Aug. 14, 1985, Sworn Statement of Formula of Slo-Fluoride™ Tablet, Sodium Fluoride 25 mg., Carnauda Wax 100 mg., Talc 11 mg., Sugar 90 mg., Magnesium Stratate 4 mg.
- Pak et al., J. Bone & Mineral Res., 1(6): 563-571, (1986).
- Hasvold et al., "In Vitro Release and in Vivo Serum

- Fluoride Levels and Urinary Excretion After Different Sodium Fluoride Tablets", European Journal of Clinical Pharmacology, 1981, pp. 225-230.
- Moller et al., "Massive Fluorosis of Bones and Ligaments", University's Roentgen Clinic, State Hospital, Copenhagen, 1932, pp. 269-294.
- Farley et al., "Fluoride Directly Stimulates Proliferation and Alkaline Phosphatase Activity of Bone-Forming Cells", Science, vol. 222, pp. 330-332.
- Jowset et al., "Effect of Combined Therapy with Sodium Fluoride, Vitamin D and Calcium in Osteoporosis", The American Journal of Medicine, vol. 53, Jul. 1972, pp. 43-49.
- Pekkanen, "The Hidden Health Risk Most Women Face", Reader's Digest, Nov. 1985, pp. 72-77.
- The Consensus Development Conference Statement, "Osteoporosis", Apr. 2-4, 1984.
- Butz et al., "Influence of Alkaline Salts and Acetazolesamide on Urinary Excretion of Citrate and Oxalate in the Rat", Abstracts of the 5th Symposium on Experimental Urology, 1980.
- Pak et al., "The Hypercalciurias Causes, Parathyroid Functions, and Diagnostic Criteria", The Journal of

(List continued on next page.)

*Primary Examiner*—Shep K. Rose  
*Attorney, Agent, or Firm*—Arnold, White & Durkee

[57] **ABSTRACT**

A novel slow-release sodium fluoride preparation and its use. Such slow-release sodium preparation comprises carnauba wax and talc and may be used to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. Gastrointestinal side effects are minimized by limiting the amount of fluoride released in the stomach and rheumatic complications are reduced by avoiding toxic levels of fluoride in serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.

**23 Claims, 5 Drawing Sheets**